Journal article
Comparison of Etests and Vitek 2 (R) to broth microdilution for the susceptibility testing of Cryptococcus neoformans
Yesholata Mahabeer, Christina C Chang, Dianithi Naidu, Afton Dorasamy, Sharon Lewin, Thumbi Ndung'u, Mohammed-Yunus Moosa, Martyn French, Koleka Mlisana, Yacoob Coovadia
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | ELSEVIER SCIENCE INC | Published : 2014
Abstract
We determined the susceptibility of 102 clinical isolates Cryptococcus neoformans from Durban, South Africa, to amphotericin B, fluconazole, flucytosine, and voriconazole using broth microdilution (BMD) according to the Clinical and Laboratory Standards Institute M27-A3 document and compared these results with Etest and Vitek 2(®). Essential agreement (EA) of Etest and Vitek 2(®) compared to BMD was determined. Low MICs that were below the epidemiological cutoff values of the 4 antifungal agents tested were demonstrated by all isolates. The EA of Etests for fluconazole, amphotericin, and voriconazole was 95.1%, 83.3%, and 91.2%, respectively, and for Vitek 2(®) EA for fluconazole, amphoteric..
View full abstractGrants
Funding Acknowledgements
We would like to thank the study participants, the clinicians who conducted the clinical trial, and the staff from the microbiology laboratory at Inkosi Albert Luthuli Central Hospital, Durban. Funding was provided by the REACH initiative and the NHLS Research Trust We would also like to thank Dr N. Govender who provided expert technical guidance with the methodology for BMD. Finally, we would like to thank Pfizer, Groton, Connecticut, for supplying voriconazole powder for BMD.